Roche Holding AG's group revenues may have taken a thumping in the second quarter due to the expected decline in sales of COVID-19 products at its diagnostics division
Roche Eyes More Growth Opportunities For Vabysmo
Ophthalmology Drug Sales Soar In Q2
The Swiss behemoth’s top five growth drivers – Vabysmo, Ocrevus, Hemlibra, Evrysdi and Phesgo – are selling well and softening the loss in earnings from products that boomed during COVID-19.
